Page last updated: 2024-12-06
pipothiazine palmitate
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
pipothiazine palmitate: was heading 1975-94 (see under PHENOTHIAZINE TRANQUILIZERS 1975-90); use PIPOTHIAZINE to search PIPOTHIAZINE PALMITATE 1975-94; palmitate ester of pipothiazine; member of phenothiazine family of tranquilizing agents [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 37767 |
| CHEMBL ID | 2106439 |
| CHEBI ID | 135769 |
| SCHEMBL ID | 636669 |
| MeSH ID | M0224740 |
Synonyms (44)
| Synonym |
|---|
| piportil depot (tn) |
| D02680 |
| pipotiazine palmitate (usan) |
| 37517-26-3 |
| 2-(1-(3-(2-((dimethylamino)sulphonyl)-10h-phenothiazin-10-yl)propyl)piperidin-4-yl)ethyl palmitate |
| pipotiazine palmitate |
| einecs 253-536-4 |
| hexadecanoic acid, 2-(1-(3-(2-((dimethylamino)sulfonyl)-10h-phenothiazin-10-yl)propyl)-4-piperidinyl)ethyl ester |
| pipothiazine palmitate |
| pipotiazine palmitate [usan] |
| 10-(3-(4-(2-hydroxyethyl)piperidino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide palmitate (ester) |
| rp 19552 |
| il 19552 |
| CHEBI:135769 |
| 2-[1-[3-[2-(dimethylsulfamoyl)phenothiazin-10-yl]propyl]piperidin-4-yl]ethyl hexadecanoate |
| NCGC00182048-01 |
| dtxcid8028896 |
| dtxsid5048970 , |
| tox21_113420 |
| cas-37517-26-3 |
| CHEMBL2106439 |
| rp-19552 |
| pipotiazine palmitic ester |
| AKOS015962982 |
| pipothiazin palmitate |
| 4q3h01qrmi , |
| unii-4q3h01qrmi |
| pipotiazin retard |
| 19552 rp |
| il-19552 |
| piportil depot |
| FT-0673939 |
| SCHEMBL636669 |
| pipotiazine palmitate [who-dd] |
| pipotiazine palmitic ester [mi] |
| pipotiazine palmitate [mart.] |
| 10-[3-[4-(2-hydroxyethyl)piperidino]propyl]-n,n-dimethylphenothiazine-2-sulfonamide palmitate (ester) |
| AC-1270 |
| sr-01000944866 |
| SR-01000944866-1 |
| 2-[1-[3-[2-[(dimethylamino)sulphonyl]-10h-phenothiazin-10-yl]propyl]piperidin-4-yl]ethyl palmitate |
| pipotiazine-palmitate |
| Q27260354 |
| 2-[1-[3-[2-[(dimethylamino)sulphonyl]-10h-phenothiazin-10-yl]propyl]piperidin-4-yl]ethylpalmitate |
Research Excerpts
Overview
Pipothiazine palmitate is a depot from the phenothiazin family of antipsychotic drugs.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Pipothiazine palmitate is a depot from the phenothiazine family of antipsychotic drugs." | ( Depot pipothiazine palmitate and undeclynate for schizophrenia. David, A; Quraishi, S, 2000) | 1.51 |
| "Pipothiazine palmitate is a depot from the phenothiazine family of antipsychotic drugs." | ( Depot pipothiazine palmitate and undecylenate for schizophrenia. David, A; Quraishi, S, 2001) | 1.51 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 28.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.22) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (33.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (66.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||